Search Within

Andrew D Seidman

  1. "Gynecologic Medicine Service"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (6)
Groups
  1. Breast Medicine Service (18)
  2. Department of Medicine (18)
  3. Gynecologic Medicine Service (18)
  4. Solid Tumor Oncology Division (18)
  5. Survivorship Research (18)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (11)

More Groups

People
  1. Clifford Hudis (16)
  2. Gabriella D'Andrea-Carlino (12)
  3. Larry Norton (11)
  4. Monica Fornier (10)
  5. Steven Sugarman (10)
  6. Tiffany Troso-Sandoval (10)

More People

Years
  1. 2021 (1)
  2. 2018 (2)
  3. 2016 (1)
  4. 2014 (2)
  5. 2013 (1)
  6. 2012 (1)

More Years

Publications
  1. Journal of Clinical Oncology (7)
  2. Breast Cancer Research and Treatment (3)
  3. Cancer Research (3)
  4. Clinical Breast Cancer (3)
  5. Annals of Oncology (1)
  6. EJC Supplements (1)
Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (3)
  3. Elsevier Inc. (3)
  4. Springer (3)
  5. Oxford University Press (1)
  6. Pergamon-Elsevier Science Ltd (1)

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: An interim safety analysis
    Meeting Abstract

    Seidman, A. D.; Conlin, A. K.; Moynahan, M. E.; Bach, A.; Troso-Sandoval, T.; Sugarman, S.; Forero, A.; Kerr, R.; Wright, G.; Hudis, C. A.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients
    Journal Article

    Deng, G.; Vickers, A.; Yeung, S.; D'Andrea, G.; Xiao, H.; Heerdt, A.; Sugarman, S.; Troso-Sandoval, T.; Seidman, A.; Hudis, C.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Norton, L.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; George, R.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible
    Meeting Abstract

    Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save